More than half of US preclinical animal-model studies are considered irreproducible, with an estimated annual cost of $28–40 billion.1,2
While protocols may be clearly written, reproducibility often breaks down in execution. Small variations in technique, timing, and setup can lead to inconsistent results across teams and sites.